New hope for SCA patients: expanded access to investigational drug troriluzole
Disease control
AVAILABLE
This program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA) who are not eligible for other trials. SCA is a rare, progressive disease that affects coordination and balance. The goal is to provide access to a potential treatment that may he…
Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 10:06 UTC